Allurion Technologies, INC Form 4 insider transactions

Rtw Investments, Lp and 1 other reported changes in beneficial ownership of Allurion Technologies, Inc. common stock on July 21, 2026.

Allurion Technologies Director Michael R. Davin reported a series of stock transactions, including gifts and sales, following a reverse stock split.

RTW Investments and affiliated funds acquired common stock and warrants in Allurion Technologies through a private placement at $1.67 per share.

RTW Investments and its affiliated funds converted $5 million of convertible notes into Allurion Technologies common stock at $3.35 per share.

Allurion Technologies' CEO, Shantanu Gaur, recently purchased 8,000 shares of the company's common stock at an average price of $3.0605 per share.

RTW Investments, LP, along with affiliated funds, acquired a significant stake in Allurion Technologies through the conversion of convertible notes and other transactions, as detailed in a recent SEC Form 4 filing.

Allurion Technologies CEO, Shantanu Gaur, purchased 8,000 shares of common stock at $3.35 per share on March 28, 2025.

Allurion Technologies' Chief Legal Officer, Brendan M. Gibbons, was granted 306,749 restricted stock units (RSUs) on November 8, 2024.

Allurion Technologies' Chief Operating Officer, Ojas Buch, was granted 306,749 restricted stock units (RSUs) under the company's 2023 Stock Option and Incentive Plan.

Keith B Johns II, a director at Allurion Technologies, received an initial grant of 326,086 Restricted Stock Units (RSUs) as part of the company's non-employee director compensation policy.

Shantanu Gaur, CEO of Allurion Technologies, received a corrected stock option grant for 1,428,571 shares, vesting over four years, as detailed in an amended SEC Form 4/A filing.

Brendan M. Gibbons, Chief Legal Officer of Allurion Technologies, received a stock option grant for 253,807 shares, as detailed in an amended SEC Form 4/A filing.

Ojas Buch, Chief Operating Officer of Allurion Technologies, acquired stock options for 306,749 shares of common stock on June 3, 2024.

Allurion Technologies' CEO, Shantanu Gaur, was granted stock options to purchase 1,298,701 shares of common stock on May 3, 2024.

Ram Chuttani, Chief Medical Officer of Allurion Technologies, was granted stock options for 204,082 shares on May 2, 2024.

Director Milena Alberti-Perez received 75,000 Restricted Stock Units (RSUs) from Allurion Technologies, vesting annually over three years.